A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both Estudio multicéntrico, randomizado, abierto, controlado frente a un comparador activo para evaluar la eficacia, seguridad y tolerancia de taspoglutida (RO5073031) comparado con exenatida en pacientes con diabetes mellitus tipo 2 controlados inadecuadamente con metformina, tiazolidinadiona o una combinación de ambos ?Evaluar la eficacia de la taspoglutida en el control glucémico (de acuerdo a los niveles de HbA1c) después de 24 semanas de tratamiento, en comparación con la exenatida con una pauta posológica de do...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Double-blind, partially randomized, parallel group, multicenter study to assess the efficacy and safety of 100 mg and 150 mg monthly oral ibandronate in women with postmenopausal osteoporosis having completed the phase III oral ibandronate trial BM16549 To study the effect of long-term treatment with monthly oral ibandronate 100 mg and 150 mg, given as a single tablet, on lumbar spine and hip BMD and bone turnover and to assess the overall long-term ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer To compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer To determine the efficacy of bevacizumab in combination with capecitabine, based on progression free survival (PFS).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy. Maintenance Rituximab in Follicular Lymphoma (MAXIMA) To evaluate the safety of rituximab maintenance therapy following a rituximab-containing induction regimen in first line or relapsed patients with follicular Non-Hodgkin’s Lymphoma

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study in adult patients with Cardiovascular disease or at elevated risk of having Cardiovascular disease to evaluate whether the study drug (Dalcetrapib) is able to reduce the risk of experiencing a cardiovascular event in the future such as a heart attack or a stroke by raising HDL cholesterol (also called “good”cholesterol) To evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in adult patients with stable coronary heart disease (CHD), CHD risk equivalents or at elevated risk for cardi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienced patients • To evaluate the induction strategy of HAART alone (I1) compared to enfuvirtide (90 mg s.c.BID) in combination with HAART (ENF+HAART, I2) • To determine the overall induction/maintenance treatment s...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma (DLBCL) • To demonstrate superior clinical efficacy as measured by progression free survival (PFS) of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus R-CHOP alone for the treatment of pre...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis To determine the effect of RO0506997 on MS by assessing the number of new gadolinium-enhancing lesions developing while on treatment (specifically the sum of new lesions seen on the weeks 4, 8 and 12 ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with advanced gastric cancer To compare the overall survival (OS) for patients treated with capecitabine and cisplatin combined with bevacizumab, versus capecitabine and cisplatin plus placebo (for bevacizumab).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune